1
|
Vrdoljak DV, Ramljak V, Muzina D, Sarceviç B, Knezević F, Juzbasić S. Analysis of Metastatic Involvement of Interpectoral (Rotter's) Lymph Nodes Related to Tumor Location, Size, Grade and Hormone Receptor Status in Breast Cancer. TUMORI JOURNAL 2019; 91:177-81. [PMID: 15948548 DOI: 10.1177/030089160509100214] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and background This study was aimed at analyzing metastatic involvement in interpectoral (Rotter's) lymph nodes in relation to tumor location, size, grade and hormone receptor status in primary breast cancer. Methods The study included 172 female patients undergoing surgery for breast cancer at the University Hospital for Tumors, Zagreb, Croatia from November 2001 to August 2003. In addition to the standard surgical procedure, interpectoral (Rotter's) lymph nodes were removed in all of the patients. Serum levels of the tumor marker CA 15-3 were determined before surgery and hormone receptor status after surgery. Results Rotter's lymph nodes were identified in 67% of the patients, with metastatic involvement being found in 20% of the Rotter's nodes. Metastatic involvement of Rotter's nodes in patients with negative and positive axillary lymph nodes was 4% and 35%, respectively. When we looked at the location of the tumor in patients with metastatic involvement of Rotter's nodes, we found that tumors located in the upper quadrants were more prone to metastasis to Rotter's nodes; there was a significant positive correlation between tumor location and positive Rotter's nodes (r = 0.953, P = 0.012). As regards tumor size, Rotter's nodes were identified in 15%, 20% and 30% of stage T1 (<2 cm), T2 (2-5 cm) and T3 (>5 cm) tumors, respectively. Hormone receptor status showed no statistically significant difference in the expression of estrogen and progesterone receptors between patients with and those without positive Rotter's nodes. Of 35 Rotter's node-positive patients, 31.4% had elevated serum levels of CA 15-3; the level was significantly higher in Rotter's-positive patients compared to those with negative (or absent) Rotter's nodes. Conclusions The results show that one-fifth of breast cancer patients, or even one-third of those with positive axillary lymph nodes, are discharged with positive interpectoral lymph nodes that remain undiagnosed. As the nodes can be surgically removed without additional mutilation, exploration of Rotter's lymph nodes should be introduced into routine clinical practice.
Collapse
|
2
|
Fossati R, Alexanian A, Liberati A, Marsoni S, Monferroni N, Nicolucci A, Parazzini F, Giganti M, Piffanelli A, Ghezzi P, Magnanini S, Rinaldini M, Berardi F, Di Biagio G, Testore F, Tavoni N, Palmieri D, Schittulli F, Pedicini T, Fumagalli M, Gritti G, Braga M, Marini G, Zamboni A, Cosentino D, Epifani C, Scognamiglio G, Perroni D, Peradotto F, Saba V, Indelli M, Santini A, Isa L, Scapaticci R, Aitini E, Gavazzini G, Smerieri F, Lomonaco I, Nascimben O, Locatelli E, Monti M, Ghislandi E, Gottardi O, Majno M, Poma C, Pluchinotta A, Armaroli L, Confalonieri C, Viola P, Sisto R, Buda F, Plaino R, Galletto L, Trolli B, Biasio M, Rolfo A, Vaudano G, Giolito M, Scoletta G, Ambrosini G, Busana L, Molteni M, Richetti A. Breast Cancer Estrogen and Progesterone Receptors: Associations with Patients' Clinical and Epidemiologic Characteristics. TUMORI JOURNAL 2018; 77:472-8. [DOI: 10.1177/030089169107700605] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A total of 1095 patients with operable breast cancer and en-rolled in a randomized clinical trial were analysed for estrogen (ER) and progesterone (PgR) receptor content of their primary tumor, and the relationships between steroid receptor status and several epidemiologic characteristics were studied. The proportion of ER+ and median ER levels increased with age: compared to women younger than 40, those aged 66 or more were approximately three times more likely to have an ER+ tumor (OR = 3.0, 95% C.I. = 1.6–5.7). This difference tended to be more marked after comparison between patients with ER > 100 fmol/mg protein and ER- within the same age groups: OR = 7.04, 95 % C.I. = 2.89–17.12. No association emerged between age and PgR. ER status and concentrations were independent of menopausal status after adjustment for age, whereas the proportion of PgR+ and PgR levels were significantly lower in postmenopausal patients of the same age. The distribution of ER and PgR profiles was similar in relation to family history of breast cancer, reproductive events and other selected epidemiologic characteristics of the patients.
Collapse
Affiliation(s)
| | - R. Fossati
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - A.A. Alexanian
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - A. Liberati
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - S. Marsoni
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - N. Monferroni
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - A. Nicolucci
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - F. Parazzini
- G.I.V.I.O. Coordinating Center, Istituto di Ricerche Farmacologiche Mario Negri, Milano
| | - M. Giganti
- Cattedra Medicina Nucleare, Istituto Radiologia, Università degli Studi di Ferrara
| | - A. Piffanelli
- Cattedra Medicina Nucleare, Istituto Radiologia, Università degli Studi di Ferrara
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Lesar M, Stanec M, Banović M. Significance of the Relative Size of a Breast Tumor in Deciding the Method of Surgical Treatment. TUMORI JOURNAL 2018. [DOI: 10.1177/030089160609200104] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Miroslav Lesar
- Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
| | - Mladen Stanec
- Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
| | - Miroslav Banović
- Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia
| |
Collapse
|
4
|
Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis. Clin Breast Cancer 2018; 18:1-8. [DOI: 10.1016/j.clbc.2017.06.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2016] [Revised: 06/15/2017] [Accepted: 06/18/2017] [Indexed: 01/18/2023]
|
5
|
Elias JM, Qiao L, Heimann A, Engellenner W, Abel W. Paraffin Embedded Breast Carcinomas for the Immunohistochemical Study of Prognostic Factors. J Histotechnol 2013. [DOI: 10.1179/his.1992.15.4.315] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
6
|
Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 2002; 98:118-27. [PMID: 11857395 DOI: 10.1002/ijc.10171] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Breast cancers in younger, premenopausal women are more likely to exhibit an adverse prognostic profile (including negative steroid hormone receptors and a high rate of cellular proliferation) and poor outcome than breast cancers in postmenopausal women. It has been hypothesized that this adverse prognostic profile is a result of the higher histologic grade of breast cancers in pre- compared with post-menopausal women. To assess the association of expression of steroid hormone receptors and indicators of proliferation while controlling for histologic grade, we identified 100 infiltrating ductal carcinomas from premenopausal women 45 years of age or younger and 100 from postmenopausal women 65 years of age or older. The carcinomas were selected so that the histologic grades (low versus high) were distributed equally between the 2 groups. Estrogen receptors (ER), progesterone receptors (PR), p27(Kip1) and Ki-67 (to measure rate of proliferation) were assessed by immunohistochemistry and compared between groups. Clinical information and survival data were also analyzed. ER content was lower and proliferation was higher in carcinomas in premenopausal women (p = 0.048 and p = 0.005, respectively). By univariate analysis, p27(Kip1) and PR were not different between the groups; however, in multivariate analysis, p27(Kip1) was higher in postmenopausal women, but only in a subgroup with highly proliferative carcinomas. Overall survival was similar in the pre- and postmenopausal women. Furthermore, low p27(Kip1) and African-American ethnicity predicted a poorer overall survival in the premenopausal, but not in the postmenopausal, women in our study. After controlling for histologic grade, a lower expression of ER and a higher proliferative index were detected in breast carcinomas in premenopausal women. Therefore, some prognostic indicators, such as ER and proliferative rate, may be more closely associated with menopausal status than histologic grade. Our data also suggest that some prognostic factors are not equally effective as predictors of survival in pre- and postmenopausal women.
Collapse
Affiliation(s)
- Lynya I Talley
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
| | | | | | | | | | | |
Collapse
|
7
|
Rosner D, Lane WW, Nemoto T. Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study. Cancer 1989; 64:6-15. [PMID: 2731120 DOI: 10.1002/1097-0142(19890701)64:1<6::aid-cncr2820640103>3.0.co;2-l] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The predictive value of estrogen receptor (ER) level for response to chemotherapy was studied in 182 patients with metastatic breast cancer in a prospective study. Patients were stratified according to ER status and dominant site of disease and randomized to one of three regimens: cyclophosphamide, 5-Fluorouracil, and prednisone (CFP) versus CFP, methotrexate, and vincristine (CFPMV) versus doxorubicin and cyclophosphamide (AC). There was no significant differences in all response categories (P = 0.21), was taken as a predictor for response to chemotherapy, there was no significant difference in overall response (P = 0.61) between ER+ (62/108, 57%) and ER- patients (31/49, 63%). However, there was a significant trend toward a higher degree of response in ER- patients (more complete response [CR] nine of 49, 18%, and fewer failures six of 49, 12%) than in ER+ (less CR seven of 108, 7%, and more failures 37/108, 34%) (P = 0.006). Patients with higher measured levels of ER showed worse response (Kendall's tau C, P = 0.026). This trend for ER- patients to have better response than ER+ patients was generally consistent, regardless of the predominant site of metastases or chemotherapy regimen (P = 0.04 for CFP; P = 0.08 for CFPMV; and P = 0.20 for AC). The advantage of a better response for ER- patients was nullified by an earlier relapse which was reflected in longer duration of remission, time to treatment failure, and survival in favor of ER+ patients (12.3 months versus 7.3 months remission duration, 18.7 months versus 13.6 months survival in partial responders). These data suggest that ER- patients respond to a higher extent to chemotherapy but relapse sooner than ER+ patients, suggesting a more rapid growth for ER- tumors. In patients with ER- tumors and poorer prognosis on conventional chemotherapy, new trials of intensive consolidation after response should be considered.
Collapse
Affiliation(s)
- D Rosner
- Department of Breast Surgery, Roswell Park Memorial Institute, Buffalo, New York 14263
| | | | | |
Collapse
|